Biotech News
Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program in optic neuritis Oculis will host an R&D Day on December 8, 2026, to provide further updates on
